 Caladrius Biosciences NASDAQ:CLBS was downgraded by Zacks Investment Research from a hold rating to a sell rating in a report issued on Friday, Zacks.com reports. According to Zacks, Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product ... 